Topics

"Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome" Drugs and Medication Database

15:45 EST 21st January 2020 | BioPortfolio

Here are the most relevant "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome" Drugs and Medications that we have found in our database.

More Information about "Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome" on BioPortfolio

We have published hundreds of Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome news stories on BioPortfolio along with dozens of Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Clinical Trials and PubMed Articles about Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Companies in our database. You can also find out about relevant Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome Drugs and Medications on this site too.

Showing "Phase Study Recombinant Human rhIL Mogamulizumab People With" Drugs and Medications, all 2

Probably Relevant

Poteligeo [kyowa kirin, inc.]

These highlights do not include all the information needed to use POTELIGEO safely and effectively. See full prescribing information for POTELIGEO. POTELIGEO (mogamulizumab-kpkc) injection, for intravenous useInitial U.S. Approval: 2018

Possibly Relevant

Iclusig [millennium pharmaceuticals, inc.]

These highlights do not include all the information needed to use ICLUSIG safely and effectively. See full prescribing information for ICLUSIG. ICLUSIG(ponatinib) tablets, for oral use Initial U.S. Approval: 2012



Quick Search